scholarly journals CORRELATION OF BCL 2 ONCOPROTEIN EXPRESSION AND ITS PROGNOSTIC SIGNIFICANCE IN COLORECTAL CARCINOMA WITH AGE, SITE GRADE AND STAGE

2021 ◽  
pp. 1-4
Author(s):  
Aruna kumara pagalla ◽  
Prashanth Gunde ◽  
Aruna Aruna
Keyword(s):  
Colorectal Cancer ◽  
Colorectal Carcinoma ◽  
Prognostic Significance ◽  
Tnm Staging ◽  
Inclusion Criteria ◽  
Immunohistochemical Expression ◽  
Early Stages ◽  
Apoptotic Marker ◽  
Advanced Stages ◽  
Epithelial Lesions

Background & Objective: Colorectal cancer is the third most prevalent malignancy with high mortality rate, necessitating markers that predict survival and guide the treatment. Previous studies have examined the immunohistochemical expression of Bcl-2, anti apoptotic marker, in colorectal carcinoma, but results have been contradictory.To evaluate the histopathological features of colorectal carcinoma, immunohistochemical expression of Bcl-2 must be analyzed to find out statistical association of Bcl-2 expression with certain prognostic factors histopathologic type, grade and TNM staging and also clinical parameters like age gender, site. Methods: This prospective study was conducted on the colectomy specimens of colorectal carcinoma,over a period of 2 years 6months From may 2018 to November 2020 The tumor morphology and Bcl-2 status were evaluated by immunohistochemistry in each case,with the inclusion criteria of resected intestinal specimens among which only malignant epithelial lesions and exclusion of all benign lesions. Results:The study included 40 cases,with age group of patients 51-60(37.5%) years and male:female ratio of 1.2:1.Bcl-2 positivity was seen in 37.5% of the cases.Weak,moderate,and strong expression of Bcl-2 was seen in 62.5%, 25%, and 12.5% of cases respectively. Even though early stages of colorectal carcinoma showed greater frequency of Bcl-2 expression than advanced stages (25% versus 12.5%), however this association was not statistically significant. Conclusion: The expression of bcl 2 out of 40 resected specimens of colorectal carcinoma correlated with various histological and clinical paramaters .bcl 2 positivity was assessed by semiquantitaive method and its expression was decreased with increase in grade and stage of the tumour and increased with the early stages of colorectal cancer

scholarly journals Histopathological Evaluation and Analysis of Immunohistochemical Expression of Bcl-2 Oncoprotein in Colorectal Carcinoma

2019 ◽  
Vol 14 (4) ◽  
pp. 317-321
Author(s):  
Shilpa Tukaram Patil ◽  
Clement Wilfred Devadass ◽  
Prasanna Shetty Badila
Keyword(s):  
Prognostic Factors ◽  
Colorectal Carcinoma ◽  
Tumor Grade ◽  
Colorectal Carcinomas ◽  
Statistical Association ◽  
Immunohistochemical Expression ◽  
Female Ratio ◽  
Male Female Ratio ◽  
Apoptotic Marker ◽  
Advanced Stages

Introduction: Colorectal cancer is the third most prevalent malignancy with high mortality rate, necessitating markers that predict survival and guide the treatment. Previous studies have examined the immunohistochemical expression of Bcl-2, an apoptotic marker, in colorectal carcinoma, but results have been contradictory. Objectives: To evaluate the histopathological features of colorectal carcinoma, analyze the immunohistochemical expression of Bcl-2, and to find out statistical association of Bcl-2 expression with certain prognostic factors histopathologic type, grade and stage. Material and Methods: This prospective study was conducted on the colectomy specimens of colorectal carcinoma, over a period of two years. The tumor morphology and Bcl-2 status were evaluated by immunohistochemistry in each case. Results: The study included 58 cases, with mean patient age of 47.07 years and male: female ratio of 1.89:1. Bcl-2 positivity was seen in 32.7% of cases. Weak, moderate, and strong expression of Bcl-2 was seen in 12.1%, 12.1%, and 8.5% of cases respectively. Even though early stages of colorectal carcinoma showed greater frequency of Bcl-2 expression than advanced stages (36.3% versus 28%), this association was not statistically significant. Conclusion: Lack of statistically significant correlation between Bcl-2 immunohistochemical expression and prognostic parameters like tumor grade and stage, suggests that Bcl-2 immunoexpression may not be a significant prognostic marker in colorectal carcinoma. Key words: Colorectal carcinomas; Immunohistochemistry; Prognostic factors.

scholarly journals Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer

2021 ◽  
Vol 28 (4) ◽  
pp. 3139-3149
Author(s):  
Il Hwan Oh ◽  
Jung-Soo Pyo ◽  
Byoung Kwan Son
Keyword(s):  
Colorectal Cancer ◽  
Immune Cells ◽  
Prognostic Significance ◽  
Prognostic Impact ◽  
Recurrence Free Survival ◽  
Overall Survival Rate ◽  
Immunohistochemical Expression ◽  
Human Colorectal Cancer ◽  
Free Survival ◽  
Prognostic Stratification

This study aims to examine the clinicopathological and prognostic significance of the YKL-40 immunohistochemical expression of tumor and immune cells through human colorectal cancer (CRC) tissue. We performed immunohistochemistry for YKL-40 and investigated the clinicopathological and prognostic impact of the YKL-40 expression of tumor (T-YKL-40) and immune cells (I-YKL-40) in CRC. We also evaluated the correlation between YKL-40 and PD-L1 expression and the immunoscore. YKL-40 was expressed in 22.6% and 64.2% of T-YKL-40 and I-YKL-40, respectively, out of the 265 CRC tissues. The I-YKL-40 expression significantly correlated with well and moderately differentiated tumors. The PD-L1 expression in immune cells significantly correlated with the I-YKL-40 expression, but not T-YKL-40 expression (p = 0.020 and p = 0.846, respectively). The I-YKL-40 expression significantly correlated with a worse overall survival rate but not recurrence-free survival (p = 0.047 and p = 0.080, respectively). However, there was no significant correlation between the T-YKL-40 expression and survival. In CRCs with a high immunoscore, patients with I-YKL-40 expression demonstrated worse overall and recurrence-free survival than those without I-YKL-40 expression. Our results demonstrated that I-YKL-40 expression significantly correlated with tumor differentiation and PD-L1 expression in immune cells. I-YKL-40 expression can be useful for the prognostic stratification of CRC patients.

scholarly journals Prognostic Value of Circulating KRAS2 Gene Mutations in Colorectal Cancer with Distant Metastases

2006 ◽  
Vol 21 (4) ◽  
pp. 223-228 ◽  
Author(s):  
C. Trevisiol ◽  
F. Di Fabio ◽  
R. Nascimbeni ◽  
L. Peloso ◽  
C. Salbe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colorectal Carcinoma ◽  
Residual Disease ◽  
Prognostic Significance ◽  
Primary Treatment ◽  
Tissue Samples ◽  
Primary Tumors ◽  
Mutational Status ◽  
Stage D ◽  
Related Survival

While tissue KRAS2 mutations have been extensively investigated, the role of circulating mutant KRAS2 gene in patients with colorectal carcinoma remains obscure. The aim of the present study was to explore the prognostic significance of circulating KRAS2 gene mutational status in subjects undergoing primary treatment for colorectal cancer. Codon 12 KRAS2 mutations were examined in DNA samples extracted from the serum of 86 patients with colorectal cancer and were compared with the KRAS2 status of their primary tumors. Tissue and serum KRAS2 status was compared with other clinicopathological variables (including CEA and CA 19-9 levels) and with cancer-related survival. KRAS2 mutations were found in tissue samples of 28 patients (33%); serum KRAS2 mutations were detected in 10 of them (36%). Serum KRAS2 status was significantly associated with Dukes' stage D (p=0.001) and with preoperative CA 19-9 levels (p=0.01). At multivariate analysis, cancer-related survival was associated with Dukes' stage (p<0.0001), CEA level (p=0.02), and mutant circulating KRAS2 (p=0.01). All 7 stage D patients with serum KRAS2 mutations died of the disease within 24 months of primary treatment; cancer-related survival was significantly better in 9 stage D patients without serum KRAS2 mutations, with 5 patients (56%) alive after 24 months and 1 patient (13%) alive after 44 months. Residual disease after surgery was evident in all 7 stage D patients with mutant circulating KRAS2, and in 5 out of 9 stage D patients without serum mutations. Serum KRAS2 status may impact substantially on the management of stage D colorectal carcinoma, since it appears to correlate with prognosis in this patient subgroup.

scholarly journals The Prognostic Significance of Hsp70 in Patients with Colorectal Cancer Patients: A PRISMA-Compliant Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Guangyu Gao ◽  
Songtao Liu ◽  
Zhen Yao ◽  
Yanyan Zhan ◽  
Wenyue Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colorectal Carcinoma ◽  
Cancer Patients ◽  
Web Of Science ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Expression Level ◽  
Hsp70 Expression ◽  
Colorectal Cancer Patients ◽  
The Relationship

Background. Hsp70 (heat shock protein 70) plays a key role in carcinogenesis and cancer progression. However, the relationship between the Hsp70 expression level and the colorectal cancer patient survival is unknown. This study is aimed at investigating the relationship between Hsp70 and the prognosis of colorectal carcinoma patients. Methods. PubMed, Web of Science, and Embase were used for systematic computer literature retrieval. Stata SE14.0 software was used for quantitative meta-analysis. Besides, data was extracted from selected articles. Relationships between Hsp70 expression level and prognosis were further studied. The hazard ratios (HRs) and 95% confidence intervals (95% CIs) were also computed. Results. A total of 11 potentially eligible studies with 2269 patients were identified in 10 tumors from PubMed, Web of Science, and Embase. Hsp70 overexpression was associated with poor overall survival (OS) and disease-free survival (DFS) in colorectal carcinoma patients (HRs, 0.65 (95% CI: 0.52-0.78) and 0.77 (95% CI: 0.23-1.32), respectively). Conclusions. Hsp70 overexpression can predict poor survival in colorectal cancer patients.

scholarly journals Tissue Specific Promoters in Colorectal Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
A. R. Rama ◽  
A. Aguilera ◽  
C. Melguizo ◽  
O. Caba ◽  
J. Prados
Keyword(s):  
Colorectal Cancer ◽  
Gene Therapy ◽  
Colorectal Carcinoma ◽  
Poor Response ◽  
Suicide Gene ◽  
Current Status ◽  
Specific Expression ◽  
Specific Tumor ◽  
Advanced Stages ◽  
Therapeutic Genes

Colorectal carcinoma is the third most prevalent cancer in the world. In the most advanced stages, the use of chemotherapy induces a poor response and is usually accompanied by other tissue damage. Significant progress based on suicide gene therapy has demonstrated that it may potentiate the classical cytotoxic effects in colorectal cancer. The inconvenience still rests with the targeting and the specificity efficiency. The main target of gene therapy is to achieve an effective vehicle to hand over therapeutic genes safely into specific cells. One possibility is the use of tumor-specific promoters overexpressed in cancers. They could induce a specific expression of therapeutic genes in a given tumor, increasing their localized activity. Several promoters have been assayed into direct suicide genes to cancer cells. This review discusses the current status of specific tumor-promoters and their great potential in colorectal carcinoma treatment.

Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 3566-3566
Author(s):  
D. S. Lo ◽  
A. Pollett ◽  
S. Gallinger ◽  
L. L. Siu ◽  
R. L. Burkes
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Colon Cancer ◽  
Cancer Patients ◽  
Prognostic Significance ◽  
Tnm Staging ◽  
Stage Iii ◽  
Stage Iiic ◽  
Female Ratio ◽  
Mesenteric Tumor

3566 Background: Tumor nodules are occasionally found in adjacent mesentery of colorectal cancer specimens, but their prognostic significance is unclear. According to the TNM staging system, mesenteric nodules are classified as part of T or N categories, but clinically they are regarded to reflect a worse prognosis, more like M1. We investigated the clinical significance of mesenteric tumor nodules. Methods: We reviewed 786 patients with stage III colorectal cancer referred between 1995 and 1999. We standardized TNM staging by assigning N status based on number of definite lymph nodes. Mesenteric nodules were considered separately and not assigned to T or N categories. Survival analyses were performed. Results: Mesenteric tumor nodules were found in 116 patients (14.8%); 48 with colon cancer (41.4%) and 68 rectal cancer (58.6%). Mean age at surgery was 62.8±1.0 yrs (SE), and the male: female ratio was 1.2. All tumors were adenocarcinomas with an average size of 4.3±0.1 cm, and the majority were moderately differentiated. Resection margins were clear except in 7 cases. With respect to high risk features, 6 cases (5.2%) had bowel perforation, 12 (10.3%) obstructive symptoms, 41 (35.3%) lymphovascular invasion, and 11 (9.5%) were T4 lesions. Adjuvant chemotherapy was given to 84.8% of colon cancer patients. Two (2.9%) rectal cancer patients received neoadjuvant chemo-radiation, and 63 (92.6%) received adjuvant therapy; chemotherapy, radiation or both. In the cohort with mesenteric nodules, the median time to progression was 23.1 months; the median 5-yr disease free survival was 35%; and the median overall survival (OS) was 47.9 months, with 44% OS at 5 yrs. After TNM standardization, 19 (16.4%) patients were down-staged to either stage I or II, and their 5-yr OS was 60% (SEER Stage II 5 yr survival 82.5%). In the remaining cohort-patients with stage III disease after standardization, the 5-yr OS was 40% (SEER 5yr survival Stage IIIc 44.3%; Stage IV 8.1%). Conclusions: In comparison to SEER survival data, the presence of mesenteric nodules appears to worsen prognosis of any T/N0 disease to that of overall stage III disease. Patients with mesenteric nodules in the setting of any T/N1+ disease had prognosis similar to that of stage IIIC disease, but their prognosis was better than M1 disease. No significant financial relationships to disclose.

scholarly journals Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis

2020 ◽  
Vol 8 (2) ◽  
pp. e001294 ◽  
Author(s):  
Reem Saleh ◽  
Varun Sasidharan Nair ◽  
Salman M Toor ◽  
Rowaida Z Taha ◽  
Khaled Murshed ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cell ◽  
T Cell Activation ◽  
Poor Prognosis ◽  
Prognostic Significance ◽  
Prognostic Indicator ◽  
Gene Signature ◽  
Primary Therapy ◽  
Extrinsic Factors ◽  
Advanced Stages

BackgroundCytotoxic CD8+ T cell-mediated response is the most important arm of adaptive immunity, which dictates the capacity of the host immune response in eradicating tumor cells. Due to tumor intrinsic and/or extrinsic factors, the density and function of CD8+ tumor-infiltrating lymphocytes (TILs) could be compromised, leading to poor prognosis and survival.MethodsUsing RNA-Seq, transcriptomes of sorted CD3+CD8+ TILs from treatment-naïve colorectal cancer (CRC) patients at advanced stages (III and IV) were compared with those from patients with early stages (I and II). A signature referred to as ‘poor prognosis CD8 gene signature (ppCD8sig)’ was identified and analyzed in The Cancer Genome Atlas CRC dataset. Scores for the ppCD8sig were calculated and classified as high, intermediate and low, and its prognostic significance was assessed using multivariate analysis and Cox proportional hazard model. Densities of CD3+ and CD8+ T cell infiltration in tumors from patients with high and low ppCD8sig scores were assessed by flow cytometry and immunostaining.ResultsGenes related to epigenetic regulation and response to hypoxia were upregulated in CD8+ TILs from patients with advanced stages, while genes related to T cell activation, cell proliferation and cell cycle were downregulated. Patients with high ppCD8sig score had poorer disease-specific survival (DSS) and shorter progression-free interval (PFI). The ppCD8sig was an independent prognostic indicator for DSS (HR 1.83, 95% CI 1.40 to 2.38, p<0.0001) and PFI (HR 1.42, 95% CI 1.04 to 1.93, p=0.026). Additionally, patients with high ppCD8sig score were more likely to have advanced stages (χ2 p<0.0001) and residual disease after primary therapy (χ2 p=0.046). Patients with high ppCD8sig score had reduced levels of CD3+ and CD8+ TILs and low Immunoscores (IS), compared to patients with low ppCD8sig score.ConclusionsOur data provided insights into the altered regulation of biological mechanisms and signaling pathways in CD8+ TILs during CRC progression, and revealed a gene signature as an independent prognostic indicator. Patients with high ppCD8sig score had lower levels of TILs and low IS. These data further confirm the prognostic value of the identified ppCD8sig and potentially highlight its clinical relevance.

scholarly journals Colorectal Cancer in Northwestern Iran

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Rahim Mahmodlou ◽  
Payvand Mohammadi ◽  
Nariman Sepehrvand
Keyword(s):  
Colorectal Cancer ◽  
Stage Iv ◽  
Staging System ◽  
Developed Countries ◽  
Large Bowel Obstruction ◽  
Tnm Staging ◽  
Presenting Symptoms ◽  
Advanced Stages ◽  
The Developed Countries ◽  
West Azerbaijan

Background. Colorectal cancer is the third most prevalent cancer worldwide, which is less common in the Middle East; its prevalence demonstrated to be 7 persons per 100,000 populations in Iran. In this study, we aimed to investigate the clinicopathologic features of CRC patients in West Azerbaijan province of Iran. Methods. In this crosssectional study, 546 patients who underwent surgical procedures with the pathologic diagnosis of colorectal cancer in both academic and private hospitals of Urmia were enrolled. Results. The mean age at diagnosis was 55.2 ± 11.5 years. 23% had an age lower than forty years old. Rectal bleeding (26%), abdominal pain (25%), and large bowel obstruction (23%) were three most common presenting symptoms. 26% of patients presented with acute abdomen. 95% of tumors were adenocarcinoma, 4% were lymphoma, and 1% was other rare tumors. Regarding the stage of cancer according to TNM staging system, 6% of patients were in stage I, followed by 37% in stage II, 33% in stage III, and 24% in stage IV. In 44.5% of patients, the tumor was located in rectum. Conclusion. In west Azerbaijan province of Iran, patients with colorectal cancer present in younger age and more advanced stages in comparison with the developed countries.

scholarly journals Past, Present and Future? of Colorectal Cancer Epidemiology and Clinical Study in Misan

2018 ◽  
Vol 4 ◽  
Author(s):  
Hayder Qasim Saadoon Alhilfi ◽  
Khalid Obiad Mohsin Almohammadawi ◽  
Nyaz Ahmed Ameen ◽  
Basima Kadhim Abbood Aliedani ◽  
Husam Jihad Imran Aldubaisi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Family History ◽  
Colorectal Carcinoma ◽  
Past History ◽  
Stage Iv ◽  
Smoking History ◽  
History Of ◽  
Advanced Stages ◽  
Colon And Rectum ◽  
Prostate Cancers

Background: Colorectal carcinoma is commonest cancer of GIT. It is represent third cancer in man worldwide beyond lung and prostate cancers. It is fourth cancer in woman beyond breast, lung and uterus cancers. Deaths from colorectal cancer is more in compare with other GIT cancers. The study aimed to determine epidemiological and clinical data of colorectal cancer in Misan province.Methods: Our study conducted in Misan province, Iraq. The data were collected from 2013 to 2016. Seventy one patients that found have colorectal cancer. An epidemiological, clinical and descriptive study perform which included frequency of gender, age, residency, site of cancer, family history, past history, year of onset, smoking history, alcohol intake, presentation of cancer at time of diagnosis, staging and histopathology pattern in relation to colorectal cancer.Results: Overall prevalence of colon and rectum carcinoma is 3.75%. The most age group affected was 51-60 years as 30.99%. The gender and residency of patients have no effect on cancer percent. Obesity, Family history, cigarette smoking and alcohol consumption represented risk factors for colorectal cancer. In 42.25% of patients had family history of cancer. Most common site of colorectal carcinoma was left colon, which present in 61.97%. Conclusion: There was slight increase in new cases detection of colorectal carcinoma from 2013 to 2016. Advanced stages of colorectal cancer were most common stages description as stage IIIA, IIIB, IIIC and stage IV in 12.67%, 16.90%, 19.72% and 15.49% respectively. The common histopathological pattern of colorectal cancer was moderately differentiated adenocarcinoma as 53.52%.

Sign in / Sign up

Export Citation Format

Share Document